Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Likely Received Nasdaq Warning Letter; Stock Below $1 for 30 Days

NEW YORK, Sept. 12 - Lynx Therapeutics yesterday likely received a warning letter from the Nasdaq exchange for failing to keep its share price above $1 for 30 consecutive days.


Lynx shares closed at $.46 on Tuesday, making it 30 consecutive trading days the stock has been below $1 since it slid to $.96 on July 30. If in fact Lynx received the letter the company became the third Genome Technology Index firm to get one.


Genomic Solutions, which received its warning on June 14, was acquired within one month by Harvard Bioscience. The second company, InforMax, likely received a Nasdaq letter on or around Aug. 5, which marked the thirtieth consecutive day the company's stock traded below $1.


Shares in Lynx closed at $.46 yesterday.


Companies that receive a warning letter typically have 90 days to get their share price trading above that minimum price or risk being delisted to the over-the-counter market.


According to Burrill & Company, Lynx "shed the highest percentage" of its value during August. The "beleaguered" company's stock fell 54 percent between July and August, Burrill reported.


Officials at Lynx, based in Hayward, Calif., were not available for comment at deadline this morning. Nasdaq officials are barred from discussing companies traded on the exchange.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.